Isis Pharmaceuticals partner Biogen has commenced a Phase I / II clinical trial of ISIS-SOD1Rx (BIIB067) for patients with amyotrophic lateral sclerosis (ALS).

ALS is a rare and fatal neurodegenerative disorder.

Formely known as ISIS-BIIB3Rx, the ISIS-SOD1Rx is a Gen. 2.0+ antisense drug, which is designed to reduce the production of superoxide dismutase 1 (SOD1).

ISIS-SOD1Rx is part of the firms’ strategic collaboration, which was established to develop antisense drugs to treat neurological diseases.

Isis Pharmaceuticals research senior vice-president Dr Frank Bennett said: "There is substantial evidence that mutations in the SOD1 gene are responsible for a toxic gain of function that can lead to progressive loss of motor neurons in patients with SOD1-ALS.

"Together with Biogen, we have made significant progress."

"As a result, patients with SOD1-ALS experience muscle weakness, loss of movement, difficulty in breathing and swallowing and eventually succumb to their disease."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company has designed the Phase I / II clinical trial to assess the safety and activity of ISIS-SOD1Rx in patients with ALS, including patients with SOD1-ALS.

In the trial, ISIS-SOD1Rx will be injected directly into the cerebral spinal fluid.

According to Isis, the intrathecal administration of other antisense drugs has been shown to be well tolerated in multiple clinical studies.

Isis Pharmaceuticals COO Lynne Parshall said: "Together with Biogen, we have made significant progress developing antisense drugs to treat neurological and neuromuscular disorders."